title: Can ReoPro repolish tarnished monoclonal therapeutics?
authors.forename: V
authors.initials: V
authors.lastname: Glaser
mesh_terms: D000077284:Abciximab; D017130:Angioplasty / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001709:Biotechnology; D002986:Clinical Trials as Topic; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000517:prevention & control
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab